Traws Pharma Inc (TRAW)

$TRAW $TRAW Best Healthcare funds on earth entered in December at $8.80. TWO antivirals may be worth BILLIONS. CEO was head of merger/acquisition for Merck. CMO is former CDC Director Redfield. BIRD FLU drug has shown TREMENDOUS EFFICACY. Potential market for the two antivirals is BILLIONS🐓🦠🔥

$TRAW Scam! 😂

$TRAW Nuff said…🚀🔥

$TRAW My yearly penance to remind folks that this is absolute scam company. Before it was TRAW it was ONTX a failed phase 3 company. They change names every few years so folks forget their past scams. If you want to pump and dump it have it but, never ever believe anyone that tells you they have something in their pipeline. Chances are they have absolutely no clue what they are talking about.

$TRAW animal rule is a fact, but thats just my opinion , its a matter of when, and we will be rewarded . maybe could be weeks, maybe few months. But its necessary for global healthy. Eventually it will come. Redfield know how this things get done.

$TRAW $LAES

$TRAW Traws is going head to head with Xofluza for seasonal influenza and going up against Bird Flu in Southeast Asia. The market for flu antivirals is BILLIONS. The potential for stockpiling is BILLIONS. The potential in a pandemic is BILLIONS. Thank you for your attention to this matter. 🇺🇸🐓🦠💸⏳💎

$TRAW Traws Pharma announced multiple regulatory submissions Traws Pharma announced multiple regulatory submissions related to its antiviral pipeline. A proposed Phase 2 dose-ranging, non-inferiority study will evaluate the effects of tivoxavir marboxil, a potential best in class CAP-dependent endonuclease inhibitor, compared to XOFLUZA, in patients infected with seasonal influenza. A separate single arm will evaluate the effects of TXM in patients infected with H5N1 bird flu. The proposed study has been submitted for Human Research Ethics Committee review and is expected to enroll subjects in Australia and selected countries in Southeast Asia with high rates of human bird flu infections. Also, as a follow up to recent Pre-IND FDA interactions on TXM, Traws submitted briefing materials for a Type D meeting to enable further FDA dialog on a potential path to accelerated approval for bird flu. A proposed Phase 2 non-inferiority study will evaluate the effects of ratutrelvir, a potential best in class protease inhibitor that does not require ritonavir co-administration, compared to PAXLOVID, in newly diagnosed COVID patients. The proposed study that has been submitted for HREC review is intended to enroll patients on a 10-day treatment regimen for ratutrelvir compared to the approved 5-day regimen for PAXLOVID. In addition to efficacy and safety endpoints, the proposed study will also evaluate the rates of disease rebound as well as the incidence of Long COVID. A separate single arm will evaluate the safety and efficacy of ratutrelvir in newly diagnosed COVID patients who are ineligible for treatment with PAXLOVID.

$TRAW wish i held.